Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

A methodological framework to enhance the clinical success of cancer immunotherapy

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Kantoff, P.W. et al. N. Engl. J. Med. 363, 411–422 (2010).

    Article  CAS  Google Scholar 

  2. Hodi, F.S. et al. N. Engl. J. Med. 363, 711–723 (2010).

    Article  CAS  Google Scholar 

  3. Goldman, B. & DeFrancesco, L. Nat. Biotechnol. 27, 129–139 (2009).

    Article  CAS  Google Scholar 

  4. Hoos, A. et al. J. Immunother. 30, 1–15 (2007).

    Article  Google Scholar 

  5. Janetzki, S. et al. Cancer Immunol. Immunother. 57, 303–315 (2008).

    Article  Google Scholar 

  6. Britten, C.M. et al. Cancer Immunol. Immunother. 58, 1701–1713 (2009).

    Article  CAS  Google Scholar 

  7. Hoos, A. et al. J. Natl. Cancer Inst. 102, 1388–1397 (2010).

    Article  CAS  Google Scholar 

  8. Wolchok, J.D. et al. Clin. Cancer Res. 15, 7412–7420 (2009).

    Article  CAS  Google Scholar 

  9. Janetzki, S. et al. Immunity 31, 527–528 (2009).

    Article  CAS  Google Scholar 

  10. Guidance for industry: Clinical considerations for therapeutic cancer vaccines. (US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, September 2009).

  11. European Medicines Agency. Concept paper on the need to revise the guidelines on the evaluation of anticancer medicinal products in man. 22 July 2010. EMA/CHMP/EWP/433478/2010.

  12. Finke, L.H. et al. Vaccine 25, B97–B109 (2007).

    Article  CAS  Google Scholar 

  13. Hoos, A. et al. Semin. Oncol. 37, 533–546 (2010).

    Article  CAS  Google Scholar 

  14. Marshall, M., Ribas, A. & Huang, B. Evaluation of baseline serum C-reactive protein and benefit from tremelimumab compared to chemotherapy in first-line melanoma. Abstract no. 2609, presented at the 2010 annual meeting of the American Society Clinical Oncology, Chicago, IL, June 4–8, 2010.

  15. Robert, C. et al. N. Engl. J. Med. 364, 2517–2526 (2011).

    Article  CAS  Google Scholar 

  16. Taylor, C.F. et al. Nat. Biotechnol. 26, 889–896 (2008).

    Article  CAS  Google Scholar 

  17. Finn, O.J. N. Engl. J. Med. 358, 2704–2715 (2008).

    Article  CAS  Google Scholar 

  18. Schreiber, R., Old, L.J. & Smyth, M.J. Science 331, 1565–1570 (2011).

    Article  CAS  Google Scholar 

  19. Zitvogel, L., Kepp, O. & Kroemer, G. Nat. Rev. Clin. Oncol. 8, 151–160 (2011).

    Article  CAS  Google Scholar 

Download references


We thank all participants of the workshops and community-wide initiatives conducted by CIC and CIMT for the contribution of knowledge to this evolving methodological framework.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Axel Hoos.

Ethics declarations

Competing interests

A.H. is an employee of Bristol-Myers Squibb (BMS), a pharmaceutical company and holds stock in BMS. C.M.B. has 50% employment at Ribological (Mainz, Germany), which is a company developing vaccines to treat cancer. C.H. is cofounder and supervisory board member of Ganymed Pharmaceuticals and BioNtech (Mainz, Germany), both biotech companies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoos, A., Britten, C., Huber, C. et al. A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol 29, 867–870 (2011).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing